Avner Schlessinger

Dr. Avner Schlessinger


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2016 in MedChemComm
Verified
Journal Article
Closed access
PDF file
CCClaire Colas
Claire Colas
PUPeter Man-Un Ung
Peter Man-Un Ung
ASAvner Schlessinger
Avner Schlessinger
The human solute carrier (SLC) transporters are important targets for drug development.

1 July 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ASAvner Schlessinger
Avner Schlessinger
SYSook Wah Yee
Sook Wah Yee
ASA Sali
A Sali
KGK M Giacomini
K M Giacomini

1 July 2018 in Cell Chemical Biology
Verified
Journal Article
Closed access
PUPeter Man-Un Ung
Peter Man-Un Ung
RRRayees Rahman
Rayees Rahman
ASAvner Schlessinger
Avner Schlessinger

22 June 2023 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
ASAvner Schlessinger
Avner Schlessinger
NZNicole Zatorski
Nicole Zatorski
KHKeino Hutchinson
Keino Hutchinson
CCClaire Colas
Claire Colas

26 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HCHuan-Chieh Chien
Huan-Chieh Chien
CCClaire Colas
Claire Colas
KFKarissa Finke
Karissa Finke
SSSeth Springer
Seth Springer
LSLaura Stoner
Laura Stoner
ATAllen A. Thomas
Allen A. Thomas

3 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAnna Cichońska
Anna Cichońska
BRBalaguru Ravikumar
Balaguru Ravikumar
RARobert Allaway
Robert Allaway
FWFangping Wan
Fangping Wan
SPSungjoon Park
Sungjoon Park
TATero Aittokallio
Tero Aittokallio
Despite decades of intensive search for compounds that modulate the activity of particular protein targets, a large proportion of the human kinome remains as yet undrugged. Effective approaches are therefore required to map the massive space of unexplored compound–kinase interactions for novel and potent activities. Here, we carry out a crowdsourced benchmarking of predictive algorithms for kinase inhibitor potencies across multiple kinase families tested on unpublished bioactivity data. We find the top-performing predictions are based on various models, including kernel learning, gradient boosting and deep learning, and their ensemble leads to a predictive accuracy exceeding that of single-dose kinase activity assays. We design experiments based on the model predictions and identify unexpected activities even for under-studied kinases, thereby accelerating experimental mapping efforts. The open-source prediction algorithms together with the bioactivities between 95 compounds and 295 kinases provide a resource for benchmarking prediction algorithms and for extending the druggable kinome.